Literature DB >> 141117

Urine plasmin-like substances as an index of kidney allograft rejections.

K Fukao, N Kashiwagi, T Kajiwara, M Ishikawa, B Husberg, R Weil, T E Starzl.   

Abstract

Using solid state radioimmunoassays developed by the first author, changes in the urine level of plasmin-like substances (PLS) and fibrin degradation products (FDP) before and after human kidney transplantation were determined in 49 transplant patients. Averages of urine PLS and FDP in a normal population of 51 persons were 0.13+/-0.10 (SD) and 0.14+/-0.07 microng/ml, respectively. In all transplant patients there was an initial rise of both PLS and FDP in urine immediately after transplantation. This elevation peaked on days 4 and 5 and the PLS and FDP levels returned to normal range within 2 weeks in patients without evidence of rejeciton. A secondary rise of urine PLS was detected before or with a rise in serum creatinine in all of the patients experiencing rejections. Of 11 patients who showed a rejection episode within 2 weeks of transplantation, the secondary rise of urine PLS was detectable in 55% of the patients slightly before the serum creatinine level changes; of 6 patients with a rejection episode more than 2 weeks after transplantation, 100% showed a secondary PLS rise 6.7+/-2.3 (SE) days before the serum creatinine increased. The appearance of the secondary rise of urine FDP in the rejecting recipients was slightly later than the rise of PLS. Serial determination of urine PLS levels following human kidney transplantation appears to be an early index of rejections which occurs more than 2 weeks after transplantation, although the clinical usefulness of this measurement is probably limited.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 141117      PMCID: PMC3022435          DOI: 10.1097/00007890-197705000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  27 in total

1.  Urine fibrinogen fragments in human renal allografts. A possible mechanism of renal injury.

Authors:  W E Braun; J P Merrill
Journal:  N Engl J Med       Date:  1968-06-20       Impact factor: 91.245

2.  Histological diagnosis of rejection of renal homografts in man.

Authors:  P Kincaid-Smith
Journal:  Lancet       Date:  1967-10-21       Impact factor: 79.321

3.  Elevation in urinary and blood histamine following clinical renal transplantation.

Authors:  T C Moore; D P Thompson; R J Glassock
Journal:  Ann Surg       Date:  1971-03       Impact factor: 12.969

4.  Studies of an in vitro binding reaction between thyroid microsomes and long acting thyroid stimulator globulin (LATS). I. Development of solid-state competitive binding radioassay methods for measurement of antimicrosomal and antithyroglobuin antibodies.

Authors:  T Mori; J Fisher; J P Kriss
Journal:  J Clin Endocrinol Metab       Date:  1970-08       Impact factor: 5.958

5.  Immunofluorescent examination of biopsies from long-term renal allografts.

Authors:  J J McPhaul; F J Dixon; L Brettschneider; T E Starzl
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

6.  Typing of fibrinogen degradation products in urine in various clinical disorders.

Authors:  B N Bouma; U Hedner; I M Nilsson
Journal:  Scand J Clin Lab Invest       Date:  1971-06       Impact factor: 1.713

7.  Changes in serum immunoglobulin and complement levels following renal homotransplantation.

Authors:  P H Levine; D A Merrill; P F Kohler; H N Claman
Journal:  Transplantation       Date:  1970-08       Impact factor: 4.939

8.  Fibrinuria during renal transplantation.

Authors:  B Antoine; T Neveu; P D Ward
Journal:  Transplantation       Date:  1969-08       Impact factor: 4.939

Review 9.  Human renal allografts. The role of vascular injury in early graft failure.

Authors:  G J Busch; E S Reynolds; E G Galvanek; W E Braun; G J Dammin
Journal:  Medicine (Baltimore)       Date:  1971-01       Impact factor: 1.889

10.  Urinary fibrin-fibrinogen degradation poducts after renal homotransplantation.

Authors:  A R Clarkson; J B Morton; J D Cash
Journal:  Lancet       Date:  1970-12-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.